SOURCE: DNAPrint Genomics, Inc.

July 09, 2007 07:00 ET

DNAPrint® Genomics Announces Acceptance of Studies for Publication

SARASOTA, FL--(Marketwire - July 9, 2007) - DNAPrint® Genomics (OTCBB: DNAG), which holds two patents and has seven patent applications pending related to genetic markers, today announced that two studies performed by Company Founder and Chief Science Officer Tony Frudakis, Ph.D., will be published in peer reviewed scientific journals in the coming months.

"Multilocus OCA2 Genotypes Specify Human Iris Colors," which describes the identification of numerous new OCA2 single nucleotide polymorphism (SNP) associations with iris color and how they can be used together to predict iris color from DNA, will be published in the journal Human Genetics, a respected peer-review journal which publishes the latest research in the field.

The methods for making these predictions are part of the Company's patent-pending platform for empirically relating genotypes to phenotypes.

According to one reviewer, the manuscript "illustrates: 1) fine-phenotyping of a complex trait helps dissect the genetic factors that influence the trait; 2) simplistic interpretations for many traits will arise if the scientific community limits its studies of loci to a few associated SNPs and haplotypes." Another reviewer stated that "...this is an interesting paper. OCA2 and iris pigmentation is a great model for studying the effects of genetic variation on a complex trait."

DNAPrint's ancestry technology was crucial for identifying SNPs truly associated with iris color, as opposed to those merely correlated with iris color due to ancestry informativeness (since ancestry is itself correlated with iris color). In addition, the Company's patented Haploscope software system was crucial for identifying the most informative haplotypes.

Described for the first time in this manuscript, the method is also described in more detail in a textbook written by Dr. Frudakis to be released later in 2007.

Another article by Dr. Frudakis that describes a polymorphism associated mainly with Lipitor®-induced myalgia, originally scheduled for publication in November 2006 in the scientific journal Pharmacogenetics and Genomics, will now be published in August 2007. The journal gave no reason for the delay in publication.

Dr. Frudakis founded the company that eventually became DNAPrint® in 1998, serving as its president and chief executive officer. Prior to this, Dr. Frudakis was a research scientist for Corixa Corporation. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, magna cum laude graduate of the University of California Irvine where he received a bachelor's degree in biological sciences. His doctorate in molecular and cell biology is from the University of California Berkeley. Today, Dr. Frudakis is the Chief Science Officer, Director and founder of the company. Mr. Richard Gabriel has assumed the role of President and Chief Executive Officer.

About DNAPrint™ Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941-366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848